Alle Studien
RekrutierungPHASE3INTERVENTIONELL

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

This research study is investigating a new gene therapy called ATSN-201 for an inherited eye condition known as X-linked Retinoschisis (XLRS). XLRS affects the retina, the light-sensitive layer at the back of your eye, leading to vision problems. This study wants to find out if ATSN-201 is both safe to use and whether it can improve vision or slow down the progression of XLRS in people aged 6 and older. The treatment involves a one-time injection into the eye. Some people in the study will receive the treatment, while others won't at first, but may have the option later. Your participation could help scientists understand if this new therapy could be a future treatment option for XLRS.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Atsena Therapeutics Inc.
Einschreibeziel
97
Starten
22. Aug 2023
Geschätzte Fertigstellung
01 Apr 2033

Worum geht es in dieser Studie?

This study is looking into a new treatment called ATSN-201 for a condition called X-linked Retinoschisis, or XLRS. XLRS is a rare, inherited eye condition that mainly affects boys and men. It happens because of a problem with a specific gene (RS1), which causes layers of the retina – the light-sensitive tissue at the back of your eye – to split. This splitting can lead to blurry vision and sometimes more severe vision loss.

ATSN-201 is a type of 'gene therapy'. This means it aims to correct the underlying genetic problem causing XLRS. The idea is to deliver a healthy version of the RS1 gene into the eye, which hopefully will help the retina work better and prevent further vision problems. The study will carefully check if this treatment is safe and if it helps improve or stabilise vision in people with XLRS.

The study is divided into different parts. In one part, people will be randomly chosen to either receive the ATSN-201 treatment or to be in a group that doesn't get the treatment initially. Those who receive the treatment will have a single injection into one or both eyes, depending on their specific eye condition. Everyone involved will have regular check-ups over a year, and then follow-up for another four years to see how they are doing in the long term. This careful approach helps the researchers understand the full effects of the treatment.

Wichtige Erkenntnisse

  • This study investigates a new gene therapy (ATSN-201) for X-linked Retinoschisis (XLRS).
  • It aims to check the safety and effectiveness of the treatment in people aged 6 and over.
  • The treatment involves a one-time injection into the eye.
  • Participation includes regular check-ups over a period of about five years.
  • Some participants will receive the treatment, while others may get it later.
  • This research could help develop future treatments for XLRS.

Wer könnte berechtigt sein?

To join this study, participants generally need to be male and have been diagnosed with X-linked Retinoschisis (XLRS) caused by a problem with the RS1 gene. They need to be at least 6 years old. Your vision in the eye being studied will also need to be within a certain range – not too good, but not severely poor either. Doctors will check for specific signs of the condition in your eye, like splitting in certain areas of the retina.

There are also reasons why someone might not be able to join. For example, if you have other serious eye conditions that could make the treatment risky, or if you've had eye surgery recently. Also, if you've previously had other types of gene or cell therapy for your eyes, you wouldn't be able to take part in this particular study. The study team will review all your medical information carefully to see if it's safe and appropriate for you to participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you male and diagnosed with X-linked Retinoschisis (XLRS)?
  2. Is your XLRS caused by a problem with the RS1 gene?
  3. Are you 6 years old or older?
  4. Is your vision in the affected eye within a specific range (not too good or too bad)?
  5. Do you have signs of retinal splitting in your eye as seen by a doctor?
  6. Have you *not* had recent eye surgery or other gene therapies for your eyes?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study involves several steps. First, doctors will check if you're suitable to join. If you are, you'll be assigned to either receive the ATSN-201 treatment or to a group that doesn't get the treatment straight away. If you receive the treatment, it will be given as a single injection into one or both of your eyes.

After this, you'll have regular hospital visits and check-ups for about one year to see how you're responding and to monitor your eye health. These checks might include eye exams, vision tests, and scans of your retina. Following this initial year, there will be further check-ups over the next four years to see the long-term effects of the treatment. If you were in the group that didn't receive the treatment initially, you might have the option to receive it after the first year, if you're still eligible. The total study duration, including follow-up, could be around five years.

Potenzielle Risiken und Vorteile

Participating in any study has potential benefits and risks. A potential benefit of taking part in this study is that ATSN-201 might improve your vision or slow down the progression of your XLRS, although this is not guaranteed as it's a new treatment being tested. There are also potential risks associated with the eye injection, such as infection, bleeding, or changes in eye pressure. The study team will explain all known risks to you in detail. Remember, your participation is completely voluntary, and you are free to withdraw from the study at any time without affecting your usual medical care.

Locations (21)

  • Associated Retina Consultants
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten· Rekrutierung
  • Shiley Eye Institute
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten· Noch nicht rekrutiert
  • Children's Hospital of Los Angeles
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • Stanford University
    Verifizierte Postleitzahl
    Palo Alto, Vereinigte Staaten· Noch nicht rekrutiert
  • UC San Francisco
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Rekrutierung
  • Bascom Palmer Eye Institute
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten· Rekrutierung
  • Massachusetts Eye and Ear
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten· Rekrutierung
  • Boston Kinderkrankenhaus
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten· Noch nicht rekrutiert
  • Universität von Michigan
    Verifizierte Postleitzahl
    Ann Arbor, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic
    Verifizierte Postleitzahl
    Rochester, Vereinigte Staaten· Rekrutierung
  • Columbia University
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten· Rekrutierung
  • Flaum Eye Institute, University of Rochester
    Verifizierte Postleitzahl
    Rochester, Vereinigte Staaten· Noch nicht rekrutiert

Häufige Fragen

What is X-linked Retinoschisis (XLRS)?

XLRS is a rare, inherited eye condition that causes layers of the retina (the light-sensitive part at the back of your eye) to split, leading to vision problems.

Was ist Gentherapie?

Gene therapy is a new type of treatment that aims to fix the underlying genetic cause of a disease, in this case, by delivering a healthy gene into the eye.

Will I definitely get the treatment if I join?

Not everyone will get the active treatment straight away. Some participants will be in a group that receives the treatment, while others will be in a comparison group. However, those in the comparison group may have the option to receive the treatment later.

How is the treatment given?

The treatment, ATSN-201, is given as a single injection into the eye, specifically under the retina.

Wie lange werde ich an der Studie beteiligt sein?

You will have regular checks for one year after the treatment, followed by additional checks over the next four years, making it a commitment of around five years.

Wie Sie mehr erfahren können

Atsena Therapeutics Clinical Trials

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschis… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.